Global Overactive Bladder Market Report 2017-2027: Astellas Pharma Leads Industry Sponsors with the Highest Number of Clinical Trials, Followed by Pfizer and Allergan

This Market Spotlight report covers the Overactive Bladder market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

This Market Spotlight report covers the Overactive Bladder market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Lifestyle modifications and control techniques
Medical and surgical treatment
Products and Devices

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
After Hiccups, Astellas's Mirabegron On Course For Indian Debut?
Bluewind Medical Secures CE Mark For Tibial Neurostimulator For Overactive Bladder
Will Axonics Square Up To Medtronic In Sacral Neuromodulation Market?

LICENSING AND ASSET ACQUISITION DEALS
Roivant Launches Urovant, Gets Rights To Merck's Phase III Vibegron

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Recent events

BIBLIOGRAPHY
Prescription Information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/cdkrnp/global_overactive?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716